Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Interferon in the Therapy of Severe Coronavirus Infection Publisher



Shajari R1 ; Adeli SH1 ; Bagherzadeh M1 ; Asghari A1 ; Tabaraii R1 ; Alikhani A1 ; Jabbari A1 ; Razavinia F2 ; Shakeri M1 ; Jafari S3, 4 ; Ahmadpour S5 ; Vafaeimanesh J1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
  2. 2. Student Research Committee, Qom University of Medical Sciences, Qom, Iran
  3. 3. Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran
  4. 4. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran

Source: Journal of Education and Health Promotion Published:2023


Abstract

BACKGROUND: So far, several protocols have been used for the treatment of coronavirus disease-2019 (COVID-19). In this study, we aimed to study the effect of interferon on the treatment of hypoxemia caused by COVID-19. MATERIALS AND METHODS: This was a quasi-experiment with a nonequivalent group design. All participants were admitted to Shahid Beheshti Hospital, Qom province. In total, 60 patients were enrolled in the study, and inclusion criteria were age over 18 years, positive PCR test result, pulmonary involvement in computed tomography (CT) scan, and SpO2 level below 93%. Individuals were divided into two control (hydroxychloroquine + lopinavir/ritonavir [Kaletra]) and intervention (hydroxychloroquine + lopinavir/ritonavir [Kaletra] + interferon-β 1a [recigen]) groups. The data were analyzed in Stata/SE 14.2 using Chi-square, t-test, and Mann-Whitney U test. RESULTS: The mean ± standard deviation (SD) age of patients was 63 ± 16.12 years and 43.3% were male. In terms of outcome variables, 20% of patients in the intervention group and 53.3% of subjects in the control group died and this difference was significant (P = 0.007). According to the quick sequential organ failure assessment (qSOFA) score, the severe cases were 16.7% in the intervention group and 50% in the control group (P = 0.006). In addition, the median days of hospitalization were 11.5 days - significantly higher than those in the control group (5.5 days) (P < 0.001). CONCLUSION: Based on the results of this study, the use of interferon in the treatment of COVID-19 can improve health and reduce the severity of the disease and mortality. © 2023 Journal of Education and Health Promotion.
Other Related Docs
10. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
15. The Role of Type I Interferon in the Treatment of Covid-19, Journal of Medical Virology (2022)
19. Covid-19’S Immuno-Pathology and Cardiovascular Diseases, Journal of Investigative Medicine (2023)
20. Ten Challenging Questions About Sars-Cov-2 and Covid-19, Expert Review of Respiratory Medicine (2020)
24. Pediatric Endocrinopathies Related to Covid-19: An Update, World Journal of Pediatrics (2023)
28. Management of Environmental Health to Prevent an Outbreak of Covid-19: A Review, Environmental and Health Management of Novel Coronavirus Disease (COVID-19) (2021)
29. Do Interferons Play a Role in Covid-19?, International Journal of Clinical Practice (2021)
35. Introduction on Coronavirus Disease (Covid-19) Pandemic: The Global Challenge, Advances in Experimental Medicine and Biology (2021)